A study of axitinib, a VEGF receptor tyrosine kinase inhibitor, in children and adolescents with recurrent or refractory solid tumors: A Children’s Oncology Group phase 1 and pilot consortium trial (ADVL1315)-Reference-Cited by-同舟云学术

A study of axitinib, a VEGF receptor tyrosine kinase inhibitor, in children and adolescents with recurrent or refractory solid tumors: A Children’s Oncology Group phase 1 and pilot consortium trial (ADVL1315)

Published:2018-11-05 Issue:23 Volume:124 Page:4548-4555
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Geller James I.¹,Fox Elizabeth²,Turpin Brian K.¹,Goldstein Stuart L.¹,Liu Xiaowei³,Minard Charles G.⁴,Kudgus Rachel A.⁵,Reid Joel M.⁵,Berg Stacey L.⁴,Weigel Brenda J.⁶

Affiliation:

1. Cancer and Blood Diseases Institute, Cincinnati Children’s Hospital Medical Center University of Cincinnati Cincinnati Ohio

2. Developmental Therapeutics Children’s Hospital of Philadelphia Philadelphia Pennsylvania

3. Children’s Oncology Group Monrovia California

4. Dan L Duncan Institute for Clinical and Translational Research, Baylor College of Medicine Houston Texas

5. Department of Oncology Research Mayo Clinic Rochester Minnesota

6. Department of Pediatrics, Masonic Children’s Hospital University of Minnesota Medical Center Minneapolis Minnesota

Funder

National Cancer Institute

National Institutes of Health

Mayo Clinic

Comprehensive Cancer Center, City of Hope